Pfizer Completes $43 Billion Acquisition of Seagen

Pfizer Completes $43 Billion Acquisition of Seagen

On December 14, 2023, Pfizer completed its $43 billion acquisition of Seagen – the largest M&A deal in biopharma since 2019. The deal closed after merger reviews by competition authorities around the world. A global Compass Lexecon team comprised of personnel in the U.S., Europe, and Singapore provided economic analysis and logistical support throughout the regulatory review process.

In the U.S., a Compass Lexecon team led by Nathan Wilson supported counsel through the HSR process, developing economic evidence that showed the proposed merger would not harm competition while also aiding in the process of successfully complying with the FTC’s second request. In Europe, a Compass Lexecon team supported counsel throughout the European Commission’s Phase 1 investigation.

Nathan Wilson was supported by a team that included Erica Benton, Ian MacSwain, Allan Zhang, Alexander Collison, Showroop Pokhrel, and Josh Li. In Europe, Rameet Sangha and Kirsten Edwards-Warren were supported by a team that included Florian Mockel, Aiden Lo, Conor Duggan, and James Forster.

Compass Lexecon worked closely with Debbie Feinstein, Matt Tabas, Niels Ersbøll, and John Schmidt of Arnold & Porter; and Samantha Hynes, Florence Kuhl, and Caroline Black of Sullivan & Cromwell.